切换导航
  • 比较产品
我的购物车

EasySep™小鼠Pan-B细胞分选试剂盒

免疫磁珠负选未标记的小鼠Pan-B（CD19+、CD19+CD138+、CD138+）细胞
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #19844_C

免疫磁珠负选未标记的小鼠Pan-B（CD19+、CD19+CD138+、CD138+）细胞

产品优势

  • 操作简单、快速
  • 纯度高达98%
  • 无需分离柱
  • 获得的活细胞无标记

产品组分包括

  • EasySep™小鼠Pan-B细胞分选试剂盒（产品号 #19844）
    • EasySep™小鼠Pan-B细胞分选抗体混合物，0.5 mL
    • EasySep™ Streptavidin RapidSpheres™ 50001磁珠，1 mL
  • RoboSep™小鼠Pan-B细胞分选试剂盒（产品号 #19844RF）
    • EasySep™小鼠Pan-B细胞分选抗体混合物，0.5 mL
    • EasySep™ Streptavidin RapidSpheres™ 50001磁珠，1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™ 过滤吸头（产品号 #20125）
main product photo
New format, same high quality! You may notice that your kit contents and packaging look slightly different from previous orders. We are currently updating the format of select EasySep™ Mouse kits to remove Normal Rat Serum, as this has been found to improve cell isolation performance. With this change, all components will now be shipped in a single package.
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

EasySep™小鼠Pan-B细胞分选试剂盒，通过免疫磁珠负选，可轻松高效地从脾细胞或其他组织样本的单细胞悬液中分离高纯度的小鼠pan-B细胞（CD19+、CD19+CD138+和CD138+），包括常规B-2 B细胞、B-1 B细胞和浆细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性，已在发表的研究中广泛应用超过20年。

在该EasySep™负选流程中，非目的细胞被抗体复合物与磁珠标记。表达以下标志物的非目标细胞将被去除：CD4、CD8、CD11c、CD49b、CD90.2、Ly-6C/G（Gr-1）和TER119。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。仅需10分钟完成磁珠分选后，目的Pan-B细胞即可用于流式细胞术、培养或基于细胞的分析等下游应用。

该试剂盒也适用于分选表达CD43或CD11b的来自疾病模型的恶性细胞（B-CLL）。若仅需分离常规B细胞，我们推荐使用EasySep™小鼠B细胞分选试剂盒（产品号 #19854）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。探索为您的实验流程优化的更多产品，包括培养基、补充剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞
 
种属
小鼠
 
样本来源
其它细胞系，Spleen
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫
 

查看更多 显示更少

Data Figures

Typical EasySep™ Mouse Pan-B Cell Isolation Profile of a Non-Immunized C57BL/6 Mouse

Figure 1. Typical EasySep™ Mouse Pan-B Cell Isolation Profile of a Non-Immunized C57BL/6 Mouse

Starting with mouse splenocytes, the pan-B cell content (CD19+, CD19+CD138+, and CD138+) of the isolated fraction typically ranges from 91 - 98%.

Typical EasySep™ Mouse Pan-B Cell Isolation Profile of an Immunized C57BL/6 Mouse

Figure 2. Typical EasySep™ Mouse Pan-B Cell Isolation Profile of an Immunized C57BL/6 Mouse

Starting with mouse splenocytes, the pan-B cell content (CD19+, CD19+CD138+ and CD138+) of the isolated fraction typically ranges from 91 - 98%.

Protocol Diagram for Culturing Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

Figure 3. Protocol Diagram for Culturing Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

B cells isolated from mouse spleen using EasySep™ Mouse Pan-B Cell Isolation Kit (Catalog #19844) were cultured in complete Mouse B Cell Expansion Medium (Catalog #100-1004) as described in the Directions for Use (steps 1 - 7) of the PIS for ImmunoCult™ Mouse B Cell Expansion Kit (Catalog # 100-1003). B Cells were harvested on Day 9 for analysis. Cells can also be harvested at earlier time points depending on different applications.

Expansion of Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

Figure 4. Expansion of Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

B cells isolated from mouse spleen using EasySep™ Mouse Pan-B Cell Isolation Kit (Catalog #19844) were cultured in complete Mouse B Cell Expansion Medium (Catalog #100-1004) as described in PIS for ImmunoCult™ Mouse B Cell Expansion Kit (Catalog # 100-1003). Fold expansion of viable cells is shown with bar graphs representing the mean ± SEM (n = 8). B cells expanded 176.9 ± 29.8-fold after 9 days of culture.

Maturation of Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

Figure 5. Maturation of Mouse B Cells with ImmunoCult™ Mouse B Cell Expansion Kit

B cells isolated from mouse spleen using EasySep™ Mouse Pan-B Cell Isolation Kit (Catalog #19844) were cultured in complete Mouse B Cell Expansion Medium (Catalog #100-1004) as described in the PIS for ImmunoCult™ Mouse B Cell Expansion Kit (Catalog # 100-1003). Following staining using the protocol by Pracht et al. (Eur J Immunol, 2017), the expression of A) B220 and CD138 and B) TACI (CD267) and CD86 were analyzed by flow cytometry at several time points (data represents mean ± SEM, n = 8). An increase in CD86 cell surface expression indicates B cell activation; a decrease in B220 and an increase in CD138 and TACI cell surface expression indicate maturation of B cells to plasmablasts or plasma cells.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet 1
Product Name
EasySep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844
Lot #
1000147362 or lower
Language
English
Document Type
Product Information Sheet 2
Product Name
EasySep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844
Lot #
1000147363 or higher
Language
English
Document Type
Product Information Sheet 1
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
1000147363 or higher
Language
English
Document Type
Product Information Sheet 2
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
1000147362 or lower
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
EasySep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
RoboSep™ Mouse Pan-B Cell Isolation Kit
Catalog #
19844RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (7)

EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Mouse Cell Isolation
Brochure
Mouse Cell Isolation
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Antigen Processing and Presentation
Wallchart
Antigen Processing and Presentation
Human Immune Cytokines
Wallchart
Human Immune Cytokines
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology

Frequently Asked Questions

Can EasySep™ Streptavidin RapidSpheres™ be used for either positive or negative selection?

Currently, EasySep™ Streptavidin RapidSphere™ kits are only available for negative selection and work by targeting and removing unwanted cells.

How does the separation work?

Streptavidin RapidSphere™ magnetic particles are crosslinked to unwanted cells using biotinylated antibodies. When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a new tube.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ Streptavidin RapidSphere™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Are cells isolated using EasySep™ RapidSphere™ products FACS-compatible?

Yes. Desired cells are unlabeled and ready to use in downstream applications, such as FACS analysis.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

Publications (4)

Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity. M. G. Booty et al. Journal of immunology (Baltimore, Md. : 1950) 2022 feb

Abstract

CD8+ T cell responses are the foundation of the recent clinical success of immunotherapy in oncologic indications. Although checkpoint inhibitors have enhanced the activity of existing CD8+ T cell responses, therapeutic approaches to generate Ag-specific CD8+ T cell responses have had limited success. Here, we demonstrate that cytosolic delivery of Ag through microfluidic squeezing enables MHC class I presentation to CD8+ T cells by diverse cell types. In murine dendritic cells (DCs), squeezed DCs were ˆ¼1000-fold more potent at eliciting CD8+ T cell responses than DCs cross-presenting the same amount of protein Ag. The approach also enabled engineering of less conventional APCs, such as T cells, for effective priming of CD8+ T cells in vitro and in vivo. Mixtures of immune cells, such as murine splenocytes, also elicited CD8+ T cell responses in vivo when squeezed with Ag. We demonstrate that squeezing enables effective MHC class I presentation by human DCs, T cells, B cells, and PBMCs and that, in clinical scale formats, the system can squeeze up to 2 billion cells per minute. Using the human papillomavirus 16 (HPV16) murine model, TC-1, we demonstrate that squeezed B cells, T cells, and unfractionated splenocytes elicit antitumor immunity and correlate with an influx of HPV-specific CD8+ T cells such that >80% of CD8s in the tumor were HPV specific. Together, these findings demonstrate the potential of cytosolic Ag delivery to drive robust CD8+ T cell responses and illustrate the potential for an autologous cell-based vaccine with minimal turnaround time for patients.
View publication
Quantitative and Qualitative Analysis of Humoral Immunity Reveals Continued and Personalized Evolution in Chronic Viral Infection. N. J. Kr\autler et al." Cell reports 2020 jan

Abstract

Control of established chronic lymphocytic choriomeningitis virus (LCMV) infection requires the production of neutralizing antibodies, but it remains unknown how the ensemble of antibodies evolves during ongoing infection. Here, we analyze the evolution of antibody responses during acute or chronic LCMV infection, combining quantitative functional assays and time-resolved antibody repertoire sequencing. We establish that antibody responses initially converge in both infection types on a functional and repertoire level, but diverge later during chronic infection, showing increased clonal diversity, the appearance of mouse-specific persistent clones, and distinct phylogenetic signatures. Chronic infection is characterized by a longer-lasting germinal center reaction and a continuous differentiation of plasma cells, resulting in the emergence of higher-affinity plasma cells exhibiting increased antibody secretion rates. Taken together, our findings reveal the emergence of a personalized antibody response in chronic infection and support the concept that maintaining B cell diversity throughout chronic LCMV infection correlates with the development of infection-resolving antibodies.
View publication
Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. X. Shi et al. Molecular therapy : the journal of the American Society of Gene Therapy 2019 nov

Abstract

Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.
View publication
View All Publications

更多信息

更多信息
Species Mouse
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
Sample Source Other, Spleen
Selection Method Negative
标记抗体
  1. 抗CD19抗体，克隆6D5
    抗CD19抗体，克隆6D5

    抗小鼠CD19的大鼠单克隆IgG2a抗体

  2. 抗小鼠 CD138（Syndecan-1）抗体，克隆 281-2
    抗小鼠 CD138（Syndecan-1）抗体，克隆 281-2

    抗小鼠 CD138（syndecan-1）的大鼠单克隆 IgG2a 抗体

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
  • Scientists Helping Scientists™
  • ISO 13485 和 ISO 9001 质量管理体系认证
    ISO 14001 环境管理体系认证

Scientists Helping Scientists™

ISO 13485 和 ISO 9001 质量管理体系认证

ISO 14001 环境管理体系认证

版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。